Heart failure drug vericiguat put to the test in small trial

NCT ID NCT05420012

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 4 trial tested whether vericiguat, a drug already approved for heart failure, can improve blood vessel function, reduce inflammation, and enhance quality of life in 26 people with heart failure with reduced ejection fraction. Participants received either vericiguat or a placebo, and researchers measured changes in artery dilation, walking distance, and symptom scores. The study aims to identify which patients might benefit most.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
vericiguat (Verquvo)
What this could lead to
If successful, vericiguat could become a new option to improve blood vessel health and quality of life for people with heart failure.
What could go wrong
This is a small, early-phase trial with only 26 participants, so results may not apply broadly. The drug may not show meaningful benefits over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Utah Hospital

    Salt Lake City, Utah, 84132, United States

  • Veterans Affairs Salt Lake City Health Care System (VAMC)

    Salt Lake City, Utah, 84148, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.